DTech Liquidating

DTech Liquidating Assets per Share

Delisted

The Total Assets per Share of DTech Liquidating (DMTKQ) as of Nov 21, 2026 is 3.49 USD. In the previous year, Total Assets per Share was 5.78 USD — a change of -39.67% (lower).

Assets per Share

3.49USD

YoY

-39.67%

Last updated:

Total Assets per Share of DTech Liquidating is 2023 3.49 USD. Total Assets per Share of DTech Liquidating was 2022 5.78 USD. It decreases by -39.67% lower compared to the previous year.

The DTech Liquidating Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2016
0.01 USD
Jan 1, 2017
4.20 USD
Jan 1, 2018
0.35 USD
Jan 1, 2019
0.52 USD
Jan 1, 2020
2.00 USD
Jan 1, 2021
7.10 USD
Jan 1, 2022
5.78 USD
Jan 1, 2023
3.49 USD
The DTech Liquidating Assets per Share history
YEARAssets per ShareYoY
3.49USD-39.67%
5.78USD-18.61%
7.10USD+255.73%
2.00USD+283.52%
0.52USD+46.77%
0.35USD-91.56%
4.20USD+73,350.00%
0.01USD0.00%
0.01USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Total Assets per Share of DTech Liquidating is 3.49 USD in 2023.

Total Assets per Share of DTech Liquidating changed from 5.78 USD to 3.49 USD, representing a -39.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — DTech Liquidating

All Key Metrics — DTech Liquidating